Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus

Applied Microbiology and Biotechnology

Volumn 96, Issue 5, 2012, Pages 1157-1174

  Szweda, Piotr ^a   Schielmann, Marta ^a   Kotlowski, Roman ^a   Gorczyca, Grzegorz ^a   Zalewska, Magdalena ^a   Milewski, Slawomir ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Antibiotic resistance; Peptidoglycan hydrolases; Staphylococcus; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL CELLS; BACTERIAL RESISTANCE; BACTERIOSTATIC; BROAD SPECTRUM; CELL-WALL COMPONENTS; COMBINED THERAPY; ESCHERICHIA COLI EXPRESSION SYSTEMS; FOOD POISONING; HIGH SPECIFICITY; LARGE-SCALE PRODUCTION; PEPTIDOGLYCANS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ANTIBIOTICS; BACTERIA; ESCHERICHIA COLI; HYDROLASES; PATHOGENS;

ENZYME INHIBITION;

BACTERIOPHAGE LYSIN; HYDROLASE; LASA STAPHYLOLYSIN; LYSOSTAPHIN; LYSOZYME; MURAMIC ACID; N ACETYLMURAMIC ACID; PEPTIDOGLYCAN HYDROLASE; STAPHYLOCOCCAL AUTOLYSIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; BACTERIUM; CHEMOTHERAPY; DISEASE PREVALENCE; ENZYME ACTIVITY; FOOD POISONING; GENE EXPRESSION; INFECTIOUS DISEASE; PH;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BIOFILM; CYTOLYSIS; ENZYME DEGRADATION; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL WALL; DRUG SYNERGISM; ESCHERICHIA COLI; HUMANS; MICROBIAL VIABILITY; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; RECOMBINANT PROTEINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 84871037634     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4484-3     Document Type: Review

References (147)

1. Aguinaga A, Francés ML, Del Pozo JL, Alonso M, Serrera A, Lasa I, Leiva J (2011) Lysostaphin and clarithromycin: a promising combination for the eradication of Staphylococcus aureus biofilms. Int J Antimicrob Agents 37: 585-587
2. Aligholi M, Emaneini M, Jabalameli F, Shahsavan S, Dabiri H, Sedaght H (2008) Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract 17: 432-434
3. Amorena B, Gracia E, Monzon M, Leiva J, Oteiza C, Perez JL, Alabart JL, Hernandez-Yago J (1999) Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J Antimicrob Chemother 44: 43-55
4. Antignac A, Sieradzki K, Tomasz A (2007) Perturbation of cell wall synthesis suppresses autolysis in Staphylococcus aureus: evidence for coregulation of cell wall synthetic and hydrolytic enzymes. J Bacteriol 189: 7573-7580
5. Atilano ML, Pereira PM, Yates J, Reed P, Veiga H, Pinho MG, Filipe SR (2010) Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus. Proc Natl Acad Sci U S A 107: 18991-18996
6. Ayliffe GAJ (1997) The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 24 (suppl): 74-79
7. Barequet IS, Ben Simon GJ, Safrin M, Ohman DE, Kessler E (2004) Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis. Antimicrob Agents Chemother 48: 1681-1687
8. Barequet IS, Habot-Wilner Z, Mann O, Safrin M, Ohman DE, Kessler E, Rosner M (2009) Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillinresistant Staphylococcus aureus endophthalmitis in a rat model. Graefes Arch Clin Exp Ophthalmol 247: 913-917
9. Barequet IS, Bourla N, Pessach YN, Safrin M, Yankovich D, Ohman DE, Rosner M, Kessler E (2012) Staphylolysin is an effective therapeutic agent for Staphylococcus aureus experimental keratitis. Graefes Arch Clin Exp Ophthalmol 250: 223-229
10. Becker SC, Foste-Frey J, Donovan DM (2008) The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol Lett 287: 185-191
11. Becker SC, Dong S, Baker JR, Foster-Frey J, Pritchard DG, Donovan DM (2009) LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol Lett 294: 52-60
12. Belyansky I, Tsirline VB, Martin TR, Klima DA, Heath J, Lincourt AE, Satishkumar R, Vertegel A, Heniford BT (2011) The addition of lysostaphin dramatically improves survival, protects porcine biomesh from infection, and improves graft tensile shear strength. J Surg Res 171: 409-415
13. Bera A, Herbert S, Jakob A, Vollmer W, Gotz F (2005) Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol Microbiol 55: 778-787
14. Bera A, Biswas R, Herbert S, Götz F (2006) The presence of peptidoglycan O-acetyltransferase in various staphylococcal species correlates with lysozyme resistance and pathogenicity. Infect Immun 74: 4598-4604
15. Bera A, Biswas R, Herbert S, Kulauzovic E, Weidenmaier C, Peschel A, Götz F (2007) Influence of wall teichoic acid on lysozyme resistance in Staphylococcus aureus. J Bacteriol 189: 280-283
16. Biswas R, Voggu L, Simon UK, Hentschel P, Thumm G, Götz F (2006) Activity of the major staphylococcal autolysin Atl. FEMS Microbiol Lett 259: 260-268
17. Borowski J, Kamienska K, Rutecki I (1964) Methicillin-resistant staphylococci (letter). Br Med J 1: 983
18. Borysowski J, Weber-Dabrowska B, Gorski A (2006) Bacteriophage endolysins as a novel class of antibacterial agent. Exp Biol Med 231: 366-377
19. Boyle-Vavra S, Carey RB, Daum RS (2001) Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother 48: 617-625
20. Brito N, Falcon MA, Carnicero A, Gutierrez-Navarro AM, Mansito TB (1989) Purification and peptidase activity of a bacteriolytic extracellular enzyme from Pseudomonas aeruginosa. Res Microbiol 140: 125-137
21. Callewaert L, Walmagh M, Michiels CW, Lavigne R (2011) Food applications of bacterial cell wall hydrolases. Curr Opin Biotechnol 22: 164-171
22. Cavadini C, Hertel C, Hammes WP (1996) Stable expression of the lysostaphin gene meat lactobacilli by introducing deletions within the prosequence. Syst Appl Microbiol 19: 21-27
23. Cavadini C, Hertel C, Hammes WP (1998) Application of lysostaphinproducing lactobacilli to control staphylococcal food poisoning in meat products. J Food Prot 61: 419-424
24. CDC (1999) Four pediatric deaths from community-acquired methicillinresistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 48: 707-710
25. Cetin ET, Ang O (1962) Staphylococci resistant to methicillin (celbenin) (letter). Br Med J 2: 51-52
26. Chambers HF, DeLeo FR (2009) Waves of resistance: Staphylococcus aureus in the antibiotic. Nat Rev Microbiol 7: 629-641
27. Clarke AJ, Dupont C (1991) O-acetylated peptidoglycan: its occurrence, pathobiological significance, and biosynthesis. Can J Microbiol 38: 85-91
28. Climo MW, Patron RL, Goldstein BP, Archer GL (1998) Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. AntimicrobAgents Chemother 42: 1355-1360
29. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284: 1318-1322
30. Cui F, Li G, Huang J, Zhang J, Lu M, Lu W, Huang Q (2010) Extension of nasal anti-Staphylococcus aureus efficacy of lysostaphin by its incorporation into a chitosan-o/w cream. Drug Deliv 17: 617-623
31. Dajcs JJ, Hume EBH, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ (2000) Lysostaphin treatment of methicillinresistant Staphylococcus aureus keratitis in the rabbit. Investig Ophthalmol Vis Sci 41: 1432-1437
32. Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O'Callaghan RJ (2002) Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Investig Ophthalmol Vis Sci 43(12): 3712-3716
33. Daley MJ, Oldham ER (1992) Lysostaphin: immunogenicity of locally administered recombinant protein used in mastitis therapy. Vet Immunol Immunopathol 31: 301-312
34. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA (2010) Synergism between a novel chimeric lysine and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54: 1603-1612
35. de Jonge BL, Sidow T, Chang YS, Labischinski H, Berger-Bachi B, Gage DA, Tomasz A (1993) Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus. J Bacteriol 175: 2779-2782
36. DeHart HP, Heath HE, Heath LS, LeBlanc PA, Sloan GL (1995) The lysostaphin endopeptidase gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus. Appl Environ Microbiol 61: 1475-1479
37. Desbois AP, Coote PJ (2011) Bactericidal synergy of lysostaphin in combination with antimicrobial peptides. Eur J Clin Microbiol Infect Dis 30: 1015-1021
38. Donovan DM, Lardeo M, Foster-Frey J (2006) Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. FEMS Microbiol Lett 265: 133-139
39. Ehlert K, Tschierske M, Mori C, Schröder W, Berger-Bächi B (2000) Site-specific serine incorporation by Lif and Epr into positions 3 and 5 of the staphylococcal peptidoglycan interpeptide bridge. J Bacteriol 182: 2635-2638
40. Fenton M, Ross P, McAuliffe O, O'Mahony J, Coffey A (2010a) Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs 1: 9-16
41. Fenton M, Casey PG, Hill C, Gahan CG, Ross RP, McAuliffe O, O'Mahony J, Maher F, Coffey A (2010b) The truncated phage lysin CHAP(k) eliminates Staphylococcus aureus in the nares of mice. Bioeng Bugs 1: 404-407
42. Fenton M, Ross RP, McAuliffe O, O'Mahony J, Coffey A (2011) Characterization of the staphylococcal bacteriophage lysin CHAP(K). J Appl Microbiol 111: 1025-1035
43. Filatova LY, Becker SC, Donovan DM, Gladilin AK, Klyachko NL (2010) LysK, the enzyme lysing Staphylococcus aureus cells: specific kinetic features and approaches towards stabilization. Biochimie 92: 507-513
44. Firczuk M, Mucha A, Bochtler M (2005) Crystal structures of active LytM. J Mol Biol 354: 578-590
45. Fischetti VA (2008) Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 11: 393-400
46. GaierW, Vogel RF, Hammes WP (1992) Cloning and expression of the lysostaphin gene in Bacillus subtilis and Lactobacillus casei. Lett Appl Microbiol 14: 72-76
47. García P, Madera C, Martínez B, Rodríguez A, Evaristo Suárez J (2009) Prevalence of bacteriophages infecting Staphylococcus aureus in dairy samples and their potential as biocontrol agents. J Dairy Sci 92: 3019-3026
48. García P, Martínez B, Rodríguez L, Rodríguez A (2010) Synergy between the phage endolysin LysH5 and nisin to kill S. aureus in pasteurized milk. Int J Food Microbiol 141: 151-155
49. Grundling A, Missiakas DM, Schneewind O (2006) Staphylococcus aureus mutants with increased lysostaphin resistance. J Bacteriol 188: 6286-6297
50. Gu J, Xu W, Lei L, Huang J, Feng X, Sun C, Du C, Zuo J, Li Y, Du T, Li L, Han W (2011a) LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 49: 11-17
51. Gu J, Zuo J, Lei L, Zhao H, Sun C, Feng X, Du C, Li X, Yang Y, Han W (2011b) LysGH15 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice. Bioeng Bugs 2: 96-99
52. Gupta R, Prasad Y (2011a) Efficacy of polyvalent bacteriophage P-27/HP to control multidrug resistant Staphylococcus aureus associated with human infections. Curr Microbiol 62: 255-260
53. Gupta R, Prasad Y (2011b) P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections. Curr Microbiol 63: 39-45
54. Gustin JK, Kessler E, Ohman DE (1996) A substitution at His-120 in the LasA protease of Pseudomonas aeruginosa blocks enzymatic activity without affecting propeptide processing or extracellular secretion. J Bacteriol 178: 6608-6617
55. Harris RI, Nunnery AW, Riley HD (1967) Effects of lysostaphin on staphylococcal carriage in infants and children. Antimicrob Agents Chemother 7: 110-112
56. Heilmann C, Hussain M, Peters G, Götz F (1997) Evidence for autolysin-mediated primary attachment of Staphylococcus epidermidis to a polystyrene surface. Mol Microbiol 24: 1013-1024
57. Heinrich P, Rosenstein R, Bohmer M, Sonner P, Gotz F (1987) The molecular organization of the lysostaphin gene and its sequences repeated in tandem. Mol Gen Genet 209: 563-569
58. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40: 135-136
59. HorganM, O'Flynn G, Garry J, Cooney J, Coffey A, Fitzgerald GF, Ross RP, McAuliffe O (2009) Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibioticresistant staphylococci. Appl Environ Microbiol 75: 872-874
60. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycinintermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23: 99-139
61. Idelevich EA, von Eiff C, Friedrich AW, Iannelli D, Xia G, Peters G, Peschel A, Wanninger I, Becker K (2011) In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrob Agents Chemother 55: 4416-4419
62. Iversen O, Grov A (1973) Studies on lysostaphin. Separation and characterization of three enzymes. Eur J Biochem 38: 293-300
63. Jakubczak A, Szweda P, Kur J, Kleczkowski M, Franowska A (2010) Possibilities of application of recombined lysostaphin as an alternative agent in the therapy of Staphylococcus aureus mastitis. Adv Agric Sci 1: 115-120
64. Jevons MP, Coe AW, Parker MT (1963) Methicillin resistance in staphylococci. Lancet 1: 904-907
65. Jun SY, Jung GM, Son JS, Yoon SJ, Choi YJ, Kang SH (2011) Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob Agent Chemother 55: 1764-1767
66. Kerr DE, Plaut K, Bramley AJ, Williamson CM, Lax AJ, Moore K, Wells KD, Wall RJ (2001) Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Nat Biotechnol 19: 66-70
67. Kessler E, Ohman DE (2004) Staphylolysin (LasA endopeptidase). In: Barrett A, Rawlings N, Woessner J (eds) The handbook of proteolytic enzymes, vol. 1, 2nd edn. Elsevier Academic, Amsterdam, pp 1001-1003
68. Kessler E, Safrin M, Olson JC, Ohman DE (1993) Secreted LasA of Pseudomonas aeruginosa is a staphylolytic protease. J Biol Chem 268: 7503-7508
69. Kessler E, Safrin M, Gustin JK, Ohman DE (1998) Elastase and the LasA protease of Pseudomonas aeruginosa are secreted with their propeptides. J Biol Chem 273: 30225-30231
70. Kessler E, Safrin M, Blumberg S, Ohman DE (2004) A continuous spectrophotometric assay for Pseudomonas aeruginosa LasA protease (staphylolysin) using a two-stage enzymatic reaction. Anal Biochem 328: 225-232
71. Kim HK, Thammavon V, Schneewind O, Missiakas D (2011) Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 15: 92-99
72. Kiri N, Archer G, Climo MW (2002) Combination of lysostaphin with beta-lactams are synergistic against oxacillin resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 46: 2017-2020
73. Klein E, Smith DL, Laxminarayan R (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13: 1840-1846
74. Kokai-Kun JF, Walsh SM, Canturiya T, Mond JJ (2003) Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47: 1589-1597
75. Kokai-Kun JF, Chanturiya T, Mond JJ (2009) Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother 64: 94-100
76. Kurlenda J, Grinholc M (2012) Alternative therapies in Staphylococcus aureus diseases. Acta Biochim Pol 59(2): 171-184
77. Kwiatek M, Parasion S, Mizak L, Gryko R, Bartoszcze M, Kocik J (2012) Characterization of a bacteriophage, isolated from a cow with mastitis, that is lytic against Staphylococcus aureus strains. Arch Virol 157: 225-234
78. Laarman A, Milder F, von Strijp J, Rooijakkers S (2010) Complement inhibition by Gram-positive pathogens: molecular mechanisms and therapeutic implications. J Mol Med (Berl) 88: 115-120
79. Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion by human pathogens. Nat Rev Microbiol 6: 132-142
80. Langley R, Patel D, Jackson N, Clow F, Fraser JD (2010) Staphylococcal superantigen super-domains in immune evasion. Crit Rev Immunol 30: 149-165
81. LaPlante KL (2007) In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 57: 413-418
82. Loeffler A, Lloyd DH (2010) Companion animals: a reservoir for methicillin-resistant Staphylococcus aureus in the community? Epidemiol Infect 138: 606-625
83. Loessner MJ (2005) Bacteriophage endolysins - current state of research and applications. Curr Opin Microbiol 8: 480-487
84. Lowy FD (2003) Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111: 1265-1273
85. McCormick CC, Dajcs JJ, Reed JM, Marquart ME, O'Callaghan RJ (2006) The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis. Curr Eye Res 31: 225-230
86. Melchior MB, Fink-Gremmels J, Gaastra W (2006) Comparative assessment of the antimicrobial susceptibility of Staphylococcus aureus isolates from bovine mastitis in biofilm versus planktonic culture. J Vet Med B Infect Vet Public Health 53: 326-332
87. Melchior MB, Fink-Gremmels J, Gaastra W (2007) Extended antimicrobial susceptibility assay for Staphylococcus aureus isolates from bovine mastitis growing in biofilm. Vet Microbiol 125: 141-149
88. Miao J, Pangule RC, Paskaleva EE, Hwang EE, Kane RS, Linhardt RJ, Dordick JS (2011) Lysostaphin-functionalized cellulose fibers with antistaphylococcal activity for wound healing applications. Biomaterials 32: 9557-9567
89. Mierau I, Leij P, Van Swam I, Blommestein B, Floris E, Mond J, Smidt EJ (2005a) Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the case of lysostaphin. Microb Cell Fact 4: 15
90. Mierau I, Olieman K, Monfd J, Smidt EJ (2005b) Optimization of the Lactococcus lactis nisin-controlled gene expression system NICE for industrial applications. Microb Cell Fact 4: 16
91. Obeso JM, Martinez B, Rodriguez A, Garcia P (2008) Lytic activity of the recombinant staphylococcal bacteriophage phiH5 endolysin active against Staphylococcus aureus in milk. Int J Food Microbiol 128: 211-218
92. Odintsov SG, Sabala I, Marcyjaniak M, Bochtler M (2004) Latent LytM at 1.3 A resolution. J Mol Biol 16: 775-785
93. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP (2005) The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol 187: 7161-7164
94. Oldham ER, Daley MJ (1991) Lysostaphin: use of recombinant bactericidal enzyme as a mastitis therapeutic. J Dairy Sci 74: 4175-4182
95. Oshida T, Sugai M, Komatsuzawa H, Hong YM, Suginaka H, Tomasz A (1995) A Staphylococcus aureus autolysin that has an Nacetylmuramoyl- L-alanine amidase domain and an endobeta-Nacetylglucosaminidase domain: cloning, sequence analysis, and characterization. Proc Natl Acad Sci U S A 92: 285-289
96. Pal SC, Ghosh Ray BG (1964) Methicillin-resistant staphylococci. J Indian Med Assoc 42: 512-517
97. Pangule RC, Brooks SJ, Dinu CZ, Bale SS, Salmon SL, Zhu G, Metzger DW, Kane RS, Dordick JS (2010) Antistaphylococcal nanocomposite films based on enzyme-nanotube conjugates. ACS Nano 4: 3993-4000
98. Park PW, Senior RM, Griffin GL, Broekelmann TJ, Mudd MS, Mecham RP (1995) Binding and degradation of elastin by the staphylolytic enzyme lysostaphin. Int J Biochem Cell Biol 27: 139-146
99. Park PW, Pier GB, Hinkes MT, Bernfield M (2001) Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411: 98-102
100. Park T, Struck DK, Dankenbring CA, Young R (2007) The pinholin of lambdoid phage 21: control of lysis by membrane depolarization. J Bacteriol 189(24): 9135-9139
101. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA (2011) A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and - sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother 55: 738-744
102. Patron RL, Climo MW, Goldstein BP, Archer GL (1999) Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 43: 1754-1755
103. Perichon B, Courvalin P (2009) VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53: 4580-4587
104. Polak J, Della Latta P, Blackburn P (1993) In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillinresistant Staphylococcus aureus. Diagn Microbiol Infect Dis 17: 265-270
105. Quickel KE, Selden S, Caldwell JR, Nora NF, Scheffner W (1971) Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl Microbiol 22: 446-450
106. Ramadurai L, Jayaswal RK (1997) Molecular cloning, sequencing, and expression of lytM, a unique autolytic gene of Staphylococcus aureus. J Bacteriol 179: 3625-3631
107. Ramadurai L, Lockwood KJ, Nadakavukaren MJ, Jayaswal RK (1999) Characterization of a chromosomally encoded glycylglycine endopeptidase of Staphylococcus aureus. Microbiology 145: 801-808
108. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S (2007) Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage MR11. J Infect Dis 196: 1237-1247
109. Robinson JM, Hardman JK, Sloan GL (1979) Relationship between lysostaphin endopeptidase production and cell wall composition in Staphylococcus staphylolyticus. J Bacteriol 137: 1158-1164
110. Rodríguez L, Martínez B, Zhou Y, Rodríguez A, Donovan DM, García P (2011) Lytic activity of the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage vB-SauS-phiIPLA88. BMC Microbiol 11: 138-148
111. Rodriguez-Rubio L, Gutierrez D, Martínez B, Rodriguez A, Garcia P (2012) Lytic activity of LysH5 endolysin secreted by Lactococcus lactis using the secretion signal sequence of bacteriocin Lcn972. Appl Environ Microbiol 78: 3469-3472
112. Sabala I, Jonsson IM, Tarkowski A, Bochtler M (2012) Antistaphylococcal activities of lysostaphin and LytM catalytic domain. BMC Microbiol 12: 97. doi: 10.1186/1471-2180-12-97
113. Saha B, Singh AK, Ghosh A, Bal M (2008) Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 57: 72-79
114. Sass P, Bierbaum G (2007) Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol 73: 347-352
115. Schad PA, Iglewski BH (1988) Nucleotide sequence and expression in Escherichia coli of the Pseudomonas aeruginosa lasA gene. J Bacteriol 170: 2784-2789
116. Schindler CA, Schuhardt VT (1964) Lysostaphin: a new bacteriolytic agent for the Staphylococcus. Proc Natl Acad Sci U S A 51: 414-421
117. Schindler CA, Schuhardt VT (1965) Purification and properties of lysostaphin - a lytic agent for Staphylococcus aureus. Biochim Biophys Acta 97: 242-250
118. Schleifer KH, Kandler O (1972) Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev 36: 407-477
119. Sharma R, Sharma PR, Choudhary ML, Pande A, Khatri GS (2006) Cytoplasmic expression of mature glycylglycine endopeptidase lysostaphin with an amino terminal hexa-histidine in a soluble and catalytically active form in Escherichia coli. Protein Expr Purif 45: 206-215
120. Shockman GD, Holtje JV (1994) Microbial peptidoglycan (murein) hydrolases. In: Ghuysen JM, Hackenbeck R (eds) Bacterial cell wall, vol. 27. Elsevier Science, Amsterdam, pp 131-166
121. Sloan GL, Robinson JM, Kloos WE (1982) Identification of 'Staphylococcus staphylolyticus' as a biovar of Staphylococcus simulans. Int J Syst Bacteriol 32: 170-174
122. Spencer J, Murphy LM, Conners R, Sessions RB, Gamblin SJ (2010) Crystal structure of the LasA virulence factor from Pseudomonas aeruginosa: substrate specificity and mechanism of M23 metallopeptidases. J Mol Biol 396: 908-923
123. Stark FR, Thornsvard C, Flannery EP, Artestein MS (1974) Systematis lysostaphin in man: apparent antimicrobial activity in a neutropenic patient. N Engl J Med 291: 1355-1360
124. Stefani S, Goglio A (2010) Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance. Int J Infect Dis 14 (Suppl 4): S19-S22
125. Sugai M(1997) Peptidoglycan hydrolases of the staphylococci. J Infect Chemother 3: 113-127
126. Sugai M, Fujiwara T, Akiyama T, Ohara M, Komatsuzawa H, Inoue S, Suginaka H (1997) Purification and molecular characterization of glycylglycine endopeptidase produced by Staphylococcus capitis EPK1. J Bacteriol 179: 1193-1202
127. Szweda P, Kotlowski R, Kur J (2005) New effective sources of the Staphylococcus simulans lysostaphin. J Biotechnol 117: 203-213
128. Szweda P, Lacka I, Kotlowski R, Synowiecki J (2007) Protective effect of lysostaphin from Staphylococcus simulans against Staphylococcus aureus in milk and some other food products. J Food Safety 27: 265-274
129. Taiwo SS (2009) Methicillin resistance in Staphylococcus aureus: a review of the molecular epidemiology, clinical significance and laboratory detection methods. West Afr J Med 28: 281-290
130. Takac M, Blasi U (2005) Phage 68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 49: 2934-2940
131. Thumm G, Gotz F (1997) Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphyloticus. Mol Microbiol 23: 1251-1265
132. Tomasz A (2006) The staphylococcal cell wall. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI (eds) Grampositive pathogens, 2nd edn. ASM, Washington, pp 443-455
133. Udo EE, Pearman JW, Grubb WB (1993) Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 25: 97-108
134. Vanderhaeghen W, Hermans K, Haesebrouck F, Butaye P (2010) Methicillin-resistant Staphylococcus aureus (MRSA) in food production animals. Epidemiol Infect 138: 606-625
135. Vessillier S, Delolme F, Bernillon J, Saulnier J, Wallach J (2001) Hydrolysis of glycine-containing elastin pentapeptides by LasA, a metalloelastase from Pseudomonas aeruginosa. Eur J Biochem 268: 1049-1057
136. Walencka E, Sadowska B, Rozalska S, Hryniewicz W, Rozalska B (2005) Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol J Microbiol 54: 191-200
137. Walencka E, Sadowska B, Rozalska S, Hryniewicz W, Rozalska B (2006) Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin. Folia Microbiol (Praha) 51: 381-386
138. Wall RJ, Powell AM, Paape MJ, Kerr DE, Bannerman DD, Pursel VG, Wells KD, Talbot N, Hawk HW (2005) Genetically enhanced cows resist intramammary Staphylococcus aureus infection. Nat Biotechnol 23: 445-451
139. Walsh S, Shah A, Mond J (2003) Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 47: 554-558
140. Wang IN, Deaton J, Young R (2000) Holins: the protein clocks of bacterial infection. Annu Rev Microbiol 45: 799-825
141. Weese JS, van Duijkeren E (2010) Methicillin-resistant Staphylococcus aureus and Staphylococcus pseudointermedius in veterinary medicine. Vet Microbiol 140: 418-429
142. Welsch M, Salmon J (1950) Quelques aspects de la staphylolyse. Ann Inst Pasteur 79: 802-813
143. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF (2003) Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 47: 3407-3414
144. Young R, Blasi U (1995) Holins: form and function in bacteriophage lysis. FEMS Microbiol Rev 17: 191-205
145. Zhang B, Shangguan T, Ma H, Huang X, Zhang Y (2012) Lysis of mastitis pathogens isolated from dairy cow milk samples by purified recombinant lysostaphin. Afr J Biotechnol 11: 4649-4659
146. Zhou R-Q, Chen S-G, Recsei AP (1989) Prolysostaphin-processing protease from Staphylococcus simulans purification and some properties. Acta Biochim Biophys Sin 21: 65-71
147. Zygmunt WA, Tawormina PA (1972) Model for a specific enzymatic approach to infectious disease. Prog Drug Res 16: 309-333